ChromaDex (NASDAQ:CDXC) Downgraded by Zacks Investment Research to "Sell"
Zacks Investment Research downgraded shares of ChromaDex (NASDAQ:CDXC – Get Rating) from a hold rating to a sell rating in a research note issued to investors on Monday, Zacks.com reports. According to Zacks, “ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, […]